Key Takeaways
- Moderna has reached a $950 million upfront settlement with Arbutus Biopharma and Genevant Sciences, ending patent litigation over COVID vaccine technology.
- A contingent payment of up to $1.3 billion could be triggered within 90 days if Moderna’s federal appeal is unsuccessful.
- This agreement represents the pharmaceutical industry’s largest-ever patent settlement and ranks second across all sectors.
- After-hours trading saw Moderna shares climb 8.7% to reach $54.15 on the settlement news.
- The company projects cash reserves between $4.5 billion and $5 billion by the end of 2026, with overall liquidity reaching up to $5.9 billion.
Moderna has closed the chapter on a protracted intellectual property battle — and investors responded enthusiastically.
The biotech firm disclosed Tuesday evening that it has agreed to a $950 million one-time payment to Arbutus Biopharma (ABUS) and private entity Genevant Sciences, bringing closure to worldwide patent conflicts concerning its Spikevax and mResvia vaccine products.
At the heart of the legal battle was lipid nanoparticle (LNP) delivery technology, a crucial mechanism for transporting mRNA into cells. Arbutus and Genevant initiated legal action against Moderna, alleging unauthorized use of their proprietary LNP technology.
Arbutus stock declined 11% to $4.20 during extended trading following the announcement.
The $950 million settlement will be booked as an expense in the first quarter of 2026, with the full amount disbursed in the third quarter. Following this payment, Moderna will have no ongoing royalty obligations.
One condition remains outstanding. Moderna has filed an appeal with a federal circuit court, asserting limited liability under its status as a government contractor. Should the appeal fail, the company has committed to disbursing an additional $1.3 billion within a 90-day window.
The maximum potential obligation of $2.25 billion falls significantly short of worst-case scenarios. William Blair analysts observed that market participants had been preparing for potential liabilities approaching $5 billion, which would have triggered substantial liquidity challenges.
Under the agreement’s terms, Genevant is providing Moderna with a worldwide non-exclusive license for its LNP delivery platform applicable to specific mRNA vaccines. Genevant has also committed to refraining from future patent litigation against Moderna for designated patents.
Impact on Moderna’s Financial Standing
Factoring in the settlement terms, Moderna anticipates concluding 2026 with cash and cash equivalents ranging from $4.5 billion to $5 billion. The company maintains access to an existing credit line worth up to $900 million, pushing total anticipated liquidity to between $5.4 billion and $5.9 billion.
Chief Executive Stéphane Bancel stated the agreement eliminates uncertainty and enables the organization to concentrate on future priorities.
Bancel anticipates Moderna will resume revenue expansion by late 2026. The firm is working toward regulatory approval for its combined influenza-COVID vaccine and a separate flu vaccine within the current year.
Upcoming Clinical Developments and Product Pipeline
Multiple clinical trial readouts in oncology and rare disease programs are anticipated throughout 2026, which William Blair analysts identified as prospective “new long-term growth drivers.”
The settlement removes what had been a persistent concern weighing on shareholder sentiment. Moderna’s mRNA technology platform serves as the foundation for its expanding pipeline beyond coronavirus applications.
Arbutus and Genevant characterized the agreement as the pharmaceutical sector’s largest publicly disclosed patent settlement and the second-largest transaction of its kind across all industries.
Genevant’s CEO James Heyes described the outcome as “enormously gratifying,” acknowledging recognition for the firm’s role in addressing the pandemic.
Moderna shares have climbed more than 60% during the trailing 12-month period, substantially outpacing the S&P 500’s approximately 17% advance.
The $950 million single payment becomes due in the third quarter of 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
